KANG, Kyung Sun,강경선,SEO, Min Soo,서민수,PARK, Sang Bum,박상범
申请号：
KRKR2012/009903
公开号：
WO2013/077639A1
申请日:
2012.11.22
申请国别(地区):
WO
年份:
2013
代理人:
摘要：
The present invention relates to equine amniotic membrane-derived mesenchymal stem cells (eAM-MSCs) and a method for producing same. More particularly, the present invention relates to equine amniotic membrane-derived mesenchymal stem cells showing negative immunological properties on human markers CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P, and CD200, and also showing positive immunological properties on human markers CD44, CD90 and CD105. In addition, the present invention relates to equine amniotic membrane-derived mesenchymal stem cells that can be subcultured up to 14 or more times in an undifferentiated state and an ability to be differentiated into ectoblast, mesoblast and endoblast-derived cells.Linvention concerne des cellules souches mésenchymateuses issues dune membrane amniotique équine (eAM-MSC) et un procédé de production de celles-ci. Elle concerne plus particulièrement des cellules souches mésenchymateuses issues dune membrane amniotique équine, qui présentent des propriétés immunologiques négatives sur les marqueurs humains CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P et CD200, et des propriétés immunologiques positives sur les marqueurs humains CD44, CD90 et CD105. Elle concerne en outre des cellules souches mésenchymateuses issues dune membrane amniotique équine, qui peuvent faire lobjet de sous-culture jusquà 14 fois au minimum dans un état indifférencié, et peuvent être différenciées en cellules issues dectoblastes, de mésoblastes et dendoblastes.본 발명은 말과동물 양막-유래 중간엽 줄기세포(equine amniotic membrane-derived mesenchymal stem cells eAM-MSCs) 및 그의 제조방법에 관한 것이다. 보다 상세하게는, 사람 마커인 CD19, CD20, CD28, CD31, CD34, CD38, CD41a, CD62L, CD62P 및 CD200에 대하여 모두 음성의 면역학적 특성을 나타내고, 사람 마커인 CD44, CD90 및 CD105에 대하여 모두 양성의 면역학적 특성을 나타내며, 미분화 상태로 14계대 이상 배양되는 능력 및 외배엽, 중배엽 또는 내배엽 유래 세포로 분화하는 능력을 가지는, 말과동물 양막-유래 중간엽 줄기세포에 관한 것이다.
